Duyuru • May 01
Spineway SA to Report First Half, 2026 Results on Jul 30, 2026 Spineway SA announced that they will report first half, 2026 results on Jul 30, 2026 New Risk • Mar 22
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 5.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 5.4% per year for the foreseeable future. Market cap is less than US$10m (€3.13m market cap, or US$3.61m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€2.5m net loss in 2 years). Share price has been volatile over the past 3 months (9.4% average weekly change). Price Target Changed • Mar 22
Price target increased by 22% to €0.33 Up from €0.27, the current price target is provided by 1 analyst. New target price is 110% above last closing price of €0.16. Stock is up 58% over the past year. Duyuru • Mar 09
Spineway SA, Annual General Meeting, Apr 02, 2026 Spineway SA, Annual General Meeting, Apr 02, 2026. Location: 7 allee du moulin berger, batiment 7, ecully France Reported Earnings • Feb 20
Full year 2025 earnings released Full year 2025 results: Revenue: €12.4m (down 2.4% from FY 2024). Net loss: €2.24m (loss narrowed 42% from FY 2024). New Risk • Feb 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€3.64m market cap, or US$4.33m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (8.4% average weekly change). Duyuru • Jan 14
Spineway SA to Report Fiscal Year 2025 Results on Feb 17, 2026 Spineway SA announced that they will report fiscal year 2025 results on Feb 17, 2026 Reported Earnings • Aug 04
First half 2025 earnings released First half 2025 results: Revenue: €5.57m (down 16% from 1H 2024). Net loss: €1.42m (loss narrowed 58% from 1H 2024). New Risk • Jun 17
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 22x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (over 22x increase in shares outstanding). Market cap is less than US$10m (€2.86m market cap, or US$3.31m). Minor Risk Currently unprofitable and not forecast to become profitable next year (€300k net loss next year). Duyuru • May 02
Spineway SA, Annual General Meeting, Jun 04, 2025 Spineway SA, Annual General Meeting, Jun 04, 2025. Location: 7 allee du moulin berger, batiment 7, ecully France Reported Earnings • Mar 25
Full year 2024 earnings released Full year 2024 results: Revenue: €12.0m (up 5.2% from FY 2023). Net loss: €3.86m (loss narrowed 41% from FY 2023). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 6.9% growth forecast for the Medical Equipment industry in France. Duyuru • Jan 23
Spineway SA to Report Fiscal Year 2024 Results on Mar 24, 2025 Spineway SA announced that they will report fiscal year 2024 results on Mar 24, 2025 New Risk • Oct 28
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Market cap is less than US$10m (€132.6k market cap, or US$143.1k). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€300k net loss in 2 years). Duyuru • Jul 25
Spineway SA to Report First Half, 2024 Results on Sep 24, 2024 Spineway SA announced that they will report first half, 2024 results on Sep 24, 2024 Duyuru • Feb 09
Spineway SA, Annual General Meeting, Mar 25, 2024 Spineway SA, Annual General Meeting, Mar 25, 2024. Reported Earnings • Feb 09
Full year 2023 earnings released Full year 2023 results: Revenue: €10.5m (up 23% from FY 2022). Net loss: €6.51m (loss widened 108% from FY 2022). Duyuru • Jan 26
Spineway SA to Report Q4, 2023 Results on Feb 07, 2024 Spineway SA announced that they will report Q4, 2023 results on Feb 07, 2024 Duyuru • Nov 08
Spineway Sa Announces the Appointment of Sandrine Carle as Deputy Chief Executive Officer The Spineway Group announced the appointment of Sandrine Carle as Deputy Chief Executive Officer. Ms. Carle joined Spineway in July 2022, at the time of the acquisition of Spine Innovations, where she was CEO. She was instrumental in the successful integration of Spine Innovations into the Spineway Group. After earning a degree as a biomedical engineer (UT Compiègne) and an Executive MBA at HEC in Paris, Sandrine Carle worked for over 20 years in the orthopedic surgery sector, and more specifically in the spinal surgery sector at Medtronic (Europe), Kyphon (USA) and Vexim (France). She held marketing and management positions in France and the USA before being appointed CEO of Spine Innovations in 2020. Ms. Carle led the creation of this entity following a spin-off in 2020 and the development of this activity between 2020 and 2022. She led the recruitment and management of around fifteen employees, set up the functional and operational organization of the team and also obtained the company’s certification from the notified body, G-MED (France). Working alongside Stéphane Le Roux, CEO of Spineway, Sandrine Carle is responsible for conducting the Group’s overall roadmap, in particular the business development plan aimed at returning to operating breakeven, as well as all R&D projects (short, medium and long term). Duyuru • Oct 20
Spineway Group Obtains 510(K) Clearance from the US Food and Drug Administration for its VEOS Spinal Fixation System Spineway Group announced the recent 510(k) clearance from the US Food and Drug Administration (FDA) for its VEOS Spinal Fixation System. This clearance, which allows Spineway Group to market its VEOS system in the US, represents a significant achievement for the Group and reinforces its strategic approach to develop its business in the US market. This recognition also demonstrates the Group's commitment to provide innovative solutions to surgeons and to put the well-being of patients first. This innovative medical device is presented at the North American Spine Society (NASS) Congress in Los Angeles until 21 October 2023. The VEOS Spinal Fixations System is a complete platform that offers an innovative and versatile solution tailored to surgeons' needs. The VEOS platform is easy to use, fully modular and optimizes operational excellence in operating room. This new offering enables surgeons to perform open, minimally invasive and percutaneous surgery (MIS) for the treatment of a wide range of spinal pathologies, from degenerative spine to complex surgery and deformities. Reported Earnings • Sep 21
First half 2023 earnings released First half 2023 results: Revenue: €5.43m (up 51% from 1H 2022). Net loss: €1.89m (loss widened 136% from 1H 2022). New Risk • Aug 23
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€14m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 0.9% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Market cap is less than US$10m (€619.2k market cap, or US$672.6k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). New Risk • Jul 26
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 8x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€14m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Market cap is less than US$10m (€987.0k market cap, or US$1.09m). Breakeven Date Change • Apr 09
Forecast to breakeven in 2023 The analyst covering Spineway expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2023. Earnings growth of 139% is required to achieve expected profit on schedule. Reported Earnings • Feb 14
Full year 2022 earnings released Full year 2022 results: Revenue: €7.43m (up 48% from FY 2021). Net loss: €3.14m (loss widened 98% from FY 2021). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 4.4% growth forecast for the Medical Equipment industry in France. Duyuru • Feb 02
Spineway SA to Report First Half, 2023 Results on Sep 19, 2023 Spineway SA announced that they will report first half, 2023 results on Sep 19, 2023 Duyuru • Jan 25
Spineway SA to Report Fiscal Year 2022 Results on Feb 09, 2023 Spineway SA announced that they will report fiscal year 2022 results After-Market on Feb 09, 2023 Price Target Changed • Jan 20
Price target decreased to €290 Down from €400, the current price target is provided by 1 analyst. New target price is 15,576% above last closing price of €1.85. Stock is down 94% over the past year. The company is forecast to post a net loss per share of €0.53 next year compared to a net loss per share of €4.76 last year. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Sep 09
First half 2022 earnings released First half 2022 results: Revenue: €3.11m (up 27% from 1H 2021). Net loss: €803.0k (loss widened 30% from 1H 2021). Price Target Changed • Jul 26
Price target increased to €0.01 Up from €0.0084, the current price target is provided by 1 analyst. New target price is 9,900% above last closing price of €0.0001. Stock is down 93% over the past year. The company posted a net loss per share of €0.00012 last year. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Joseph Brigneaud was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 04
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: €0 (up from €0.005 loss in FY 2020). Revenue: €5.04m (up 12% from FY 2020). Net loss: €1.58m (loss narrowed 89% from FY 2020). Revenue missed analyst estimates by 39%. Earnings per share (EPS) exceeded analyst estimates. Reported Earnings • Jan 28
Full year 2020 earnings released: €0.005 loss per share (vs €0.064 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €4.51m (down 19% from FY 2019). Net loss: €14.1m (loss widened 390% from FY 2019). Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has fallen by 94% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Jan 28
Earnings beat expectations, revenue disappoints Revenue missed analyst estimates by 48%. Earnings per share (EPS) exceeded analyst estimates by 29%. Over the next year, revenue is forecast to grow 55%, compared to a 1,649% growth forecast for the Medical Equipment industry in France. Price Target Changed • Jan 27
Price target raised to €0.01 Up from €0.0084, the current price target is provided by 1 analyst. The new target price is 809% above the current share price of €0.0011. As of last close, the stock is down 82% over the past year. Reported Earnings • Oct 30
First half earnings released Over the last 12 months the company has reported total losses of €13.3m, with losses widening by 249% from the prior year. Total revenue was €5.06m over the last 12 months, down 17% from the prior year.